$BCLI
BRAINSTORM CELL THERAPEUTICS INC.

2020 Q3 Form 10-Q Financial Statement

#000110465920115097 Filed on October 15, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2019 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.620M $1.540M $1.300M
YoY Change 70.13% 22.22% -19.25%
% of Gross Profit
Research & Development $1.867M $4.008M $3.554M
YoY Change -53.42% 102.94% 140.14%
% of Gross Profit
Depreciation & Amortization $56.00K $37.00K $33.00K
YoY Change 51.35% 12.12% 6.45%
% of Gross Profit
Operating Expenses $1.867M $4.008M $3.554M
YoY Change -53.42% 102.94% 15.02%
Operating Profit -$4.485M -$5.551M -$4.857M
YoY Change -19.2% 71.75% 57.34%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00 -$80.00K -$40.00K
YoY Change -100.0% -233.33%
Pretax Income -$4.490M -$5.630M -$4.900M
YoY Change -20.25% 77.04% 58.58%
Income Tax
% Of Pretax Income
Net Earnings -$4.488M -$5.634M -$4.900M
YoY Change -20.34% 77.39% 58.58%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$144.1K -$253.0K -$225.8K
COMMON SHARES
Basic Shares Outstanding 31.15M 21.70M
Diluted Shares Outstanding 31.15M

Balance Sheet

Concept 2020 Q3 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.81M $2.130M $2.700M
YoY Change 1252.58% -80.44% -84.52%
Cash & Equivalents $24.77M $2.095M $1.126M
Short-Term Investments $4.040M $30.00K $1.580M
Other Short-Term Assets $60.00K $620.0K $920.0K
YoY Change -90.32% -50.0% -20.69%
Inventory
Prepaid Expenses
Receivables $1.470M $1.920M $1.920M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $30.34M $4.670M $5.540M
YoY Change 549.61% -63.0% -71.68%
LONG-TERM ASSETS
Property, Plant & Equipment $950.0K $3.110M $3.300M
YoY Change -69.45% 451.42% 450.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.354M $30.00K $30.00K
YoY Change 7746.67% -97.39% -96.51%
Total Long-Term Assets $2.354M $3.140M $3.320M
YoY Change -25.03% 173.52% 127.4%
TOTAL ASSETS
Total Short-Term Assets $30.34M $4.670M $5.540M
Total Long-Term Assets $2.354M $3.140M $3.320M
Total Assets $32.69M $7.810M $8.860M
YoY Change 318.58% -43.28% -57.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.283M $9.140M $8.770M
YoY Change -64.08% 251.27% 109.81%
Accrued Expenses $917.0K $1.980M $1.020M
YoY Change -53.69% 362.62% -30.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.429M $11.96M $10.54M
YoY Change -46.25% 215.48% 29.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $280.0K $2.630M $2.840M
YoY Change -89.35%
Total Long-Term Liabilities $284.0K $2.630M $2.840M
YoY Change -89.2%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.429M $11.96M $10.54M
Total Long-Term Liabilities $284.0K $2.630M $2.840M
Total Liabilities $6.713M $14.59M $13.38M
YoY Change -53.99% 284.86% 64.17%
SHAREHOLDERS EQUITY
Retained Earnings -$137.3M
YoY Change
Common Stock $163.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.98M -$6.777M -$4.516M
YoY Change
Total Liabilities & Shareholders Equity $32.69M $7.810M $8.860M
YoY Change 318.58% -43.28% -57.85%

Cashflow Statement

Concept 2020 Q3 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$4.488M -$5.634M -$4.900M
YoY Change -20.34% 77.39% 58.58%
Depreciation, Depletion And Amortization $56.00K $37.00K $33.00K
YoY Change 51.35% 12.12% 6.45%
Cash From Operating Activities -$6.924M -$3.626M -$3.508M
YoY Change 90.95% -45.01% -6478.18%
INVESTING ACTIVITIES
Capital Expenditures $88.00K $102.0K $21.00K
YoY Change -13.73% 10100.0% -90.23%
Acquisitions
YoY Change
Other Investing Activities $0.00 $1.540M $1.410M
YoY Change -100.0% -69.08% -111.0%
Cash From Investing Activities -$86.00K $1.439M $1.391M
YoY Change -105.98% -71.12% -110.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 19.63M 3.156M 5.000K
YoY Change 521.89% 6760.87% -99.96%
NET CHANGE
Cash From Operating Activities -6.924M -3.626M -3.508M
Cash From Investing Activities -86.00K 1.439M 1.391M
Cash From Financing Activities 19.63M 3.156M 5.000K
Net Change In Cash 12.62M 969.0K -2.112M
YoY Change 1202.06% -161.92% 114.63%
FREE CASH FLOW
Cash From Operating Activities -$6.924M -$3.626M -$3.508M
Capital Expenditures $88.00K $102.0K $21.00K
Free Cash Flow -$7.012M -$3.728M -$3.529M
YoY Change 88.09% -43.47% 2105.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001137883
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23174228
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31567592
dei Document Type
DocumentType
10-Q
bcli Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
P15Y
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36641
dei Entity Registrant Name
EntityRegistrantName
BRAINSTORM CELL THERAPEUTICS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-7273918
dei Entity Address Address Line1
EntityAddressAddressLine1
1325 Avenue of Americas, 28th Floor
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address City Or Town
EntityAddressCityOrTown
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10019
dei City Area Code
CityAreaCode
201
dei Local Phone Number
LocalPhoneNumber
488-0460
dei Security12b Title
Security12bTitle
Common Stock, $0.00005 par value
dei Trading Symbol
TradingSymbol
BCLI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31567592
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24770000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
536000
CY2020Q3 us-gaap Short Term Investments
ShortTermInvestments
4038000
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
33000
CY2020Q3 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
1473000
CY2019Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
2359000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
56000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
432000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
30337000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
3360000
CY2020Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
27000
CY2019Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
32000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1377000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2182000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
950000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
960000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2354000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3174000
CY2020Q3 us-gaap Assets
Assets
32691000
CY2019Q4 us-gaap Assets
Assets
6534000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3283000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14677000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
917000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1000000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1216000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1263000
CY2020Q3 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
1013000
CY2019Q4 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
714000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6429000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17654000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
284000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1103000
CY2020Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
284000
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1103000
CY2020Q3 us-gaap Liabilities
Liabilities
6713000
CY2019Q4 us-gaap Liabilities
Liabilities
18757000
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
12000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31567592
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23174228
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
163238000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
105042000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-137272000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117276000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
25978000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-12223000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32691000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6534000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13509000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11018000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1867000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4008000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6684000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4318000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2618000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1543000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20193000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15336000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4485000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5551000
bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-197000
bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
225000
CY2020Q3 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
3000
CY2019Q3 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
83000
us-gaap Net Income Loss
NetIncomeLoss
-19996000
us-gaap Net Income Loss
NetIncomeLoss
-15561000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4488000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-5634000
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.70
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.72
CY2020Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.14
CY2019Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.25
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28695540
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21630007
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31154101
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22254993
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
5016000
CY2019Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
25000
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
312000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5027000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
326000
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
53000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-4900000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-4516000
CY2019Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
217000
CY2019Q3 bcli Stock Issued During Period Value Exercise And Reissuance Of Warrants
StockIssuedDuringPeriodValueExerciseAndReissuanceOfWarrants
3126000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
30000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-5634000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-6777000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-12223000
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
390000
CY2020Q1 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
18972000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9957000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-8114000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
9011000
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
791000
CY2020Q2 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
7411000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7394000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
9822000
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1017000
CY2020Q3 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
13307000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000
CY2020Q3 bcli Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
6300000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4488000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
25978000
us-gaap Profit Loss
ProfitLoss
-19996000
us-gaap Profit Loss
ProfitLoss
-15561000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-4488000
CY2019Q3 us-gaap Profit Loss
ProfitLoss
-5634000
us-gaap Depreciation
Depreciation
155000
us-gaap Depreciation
Depreciation
114000
CY2020Q3 us-gaap Depreciation
Depreciation
56000
CY2019Q3 us-gaap Depreciation
Depreciation
37000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
25000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
2198000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
582000
CY2020Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1017000
CY2019Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
217000
CY2020Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6924000
CY2019Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3626000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
145000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
127000
CY2020Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
88000
CY2019Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
102000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
4005000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-6088000
CY2020Q3 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-2000
CY2019Q3 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-1541000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4150000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5961000
CY2020Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-86000
CY2019Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1439000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
52000
bcli Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-61000
bcli Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
187000
CY2020Q3 bcli Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-11000
CY2019Q3 bcli Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
49000
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-1267000
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-938000
CY2020Q3 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
1095000
CY2019Q3 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-290000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-11394000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
4596000
CY2020Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1321000
CY2019Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
379000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
216000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1150000
CY2020Q3 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1082000
CY2019Q3 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1036000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27615000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7969000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
35000
CY2020Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
20000
CY2019Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
30000
bcli Proceeds From At Market
ProceedsFromAtMarket
39690000
CY2020Q3 bcli Proceeds From At Market
ProceedsFromAtMarket
13307000
bcli Proceeds From Warrant Exercises Net
ProceedsFromWarrantExercisesNet
6300000
CY2020Q3 bcli Proceeds From Warrant Exercises Net
ProceedsFromWarrantExercisesNet
6300000
bcli Exercise And Reissuance Of Warrants
ExerciseAndReissuanceOfWarrants
-3126000
CY2019Q3 bcli Exercise And Reissuance Of Warrants
ExerciseAndReissuanceOfWarrants
-3126000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9957000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55999000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3161000
CY2020Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19627000
CY2019Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3156000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24234000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1153000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
12617000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
969000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
536000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
942000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12153000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1126000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24770000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2095000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24770000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2095000
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
276000
bcli Maturity Of Interest Bearing Bank Deposits
MaturityOfInterestBearingBankDeposits
P12M
CY2019 bcli Maturity Of Interest Bearing Bank Deposits
MaturityOfInterestBearingBankDeposits
P12M
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 58.3pt;"><b style="font-size:10pt;font-weight:bold;">D.     </b><b style="font-weight:bold;"> </b><b style="font-size:10pt;font-weight:bold;">Use of estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 82.8pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p>
bcli Percentage Of Royalty Payment If Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductCoveredByValidClaimOrOrphanDrugStatus
0.05
bcli Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
0.03
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1377000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1500000
us-gaap Operating Lease Payments
OperatingLeasePayments
979000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1377000
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y2M26D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0825
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
328000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1252000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1580000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
80000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1500000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10000000.0
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1250000
CY2020Q1 us-gaap Share Price
SharePrice
8.00
CY2020Q1 bcli Warrant Term
WarrantTerm
P3Y
CY2020Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
250000
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
15.00
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
121000000
CY2020Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1232613
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0173
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.58
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.63
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
2198000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
582000
us-gaap Share Based Compensation
ShareBasedCompensation
2198000
us-gaap Share Based Compensation
ShareBasedCompensation
607000
CY2020Q3 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
17146000
CY2019Q3 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
17397000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13509000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11018000

Files In Submission

Name View Source Status
0001104659-20-115097-index-headers.html Edgar Link pending
0001104659-20-115097-index.html Edgar Link pending
0001104659-20-115097.txt Edgar Link pending
0001104659-20-115097-xbrl.zip Edgar Link pending
bcli-20200930.xsd Edgar Link pending
bcli-20200930x10q.htm Edgar Link pending
bcli-20200930x10q_htm.xml Edgar Link completed
bcli-20200930xex31d1.htm Edgar Link pending
bcli-20200930xex31d2.htm Edgar Link pending
bcli-20200930xex32d1.htm Edgar Link pending
bcli-20200930xex32d2.htm Edgar Link pending
bcli-20200930_cal.xml Edgar Link unprocessable
bcli-20200930_def.xml Edgar Link unprocessable
bcli-20200930_lab.xml Edgar Link unprocessable
bcli-20200930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending